Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy InMed Pharmaceuticals stock in Canada | $1.82

Own InMed Pharmaceuticals shares in just a few minutes.

InMed Pharmaceuticals Inc
- $0.01 ( - 0.55%)

InMed Pharmaceuticals is a biotechnology business based in the US. InMed Pharmaceuticals stocks (INM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.92 – a decrease of 6.19% over the previous week. InMed Pharmaceuticals employs 0 staff and has a market cap (total outstanding stock value) of $16.3 million.

How to buy InMed Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: INM in this case.
  5. Research InMed Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your InMed Pharmaceuticals stocks. It's that simple.

Is it a good time to buy InMed Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

InMed Pharmaceuticals stock price

Use our graph to track the performance of INM stocks over time.

InMed Pharmaceuticals stocks at a glance

Information last updated 2021-09-25.
Latest market close$1.82
52-week range$1.76 - $5.661
50-day moving average $2.1928
200-day moving average $2.917
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.52

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.
An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

InMed Pharmaceuticals price performance over time

Historical closes compared with the last close of $1.82

1 week (2021-09-20) -6.19%
1 month (2021-08-27) -25.41%
3 months (2021-06-25) -36.36%
6 months (2021-03-26) -47.40%

InMed Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -68.83%
Return on equity TTM -150.84%
Profit margin 0%
Book value $0.916
Market capitalisation USD$16.3 million

TTM: trailing 12 months

How to short and sell InMed Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "INM.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 23,132 InMed Pharmaceuticals stocks held short by investors – that's known as InMed Pharmaceuticals's "short interest". This figure is 216% up from 7,320 last month.

There are a few different ways that this level of interest in shorting InMed Pharmaceuticals stocks can be evaluated.

InMed Pharmaceuticals's "short interest ratio" (SIR)

InMed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of InMed Pharmaceuticals stocks currently shorted divided by the average quantity of InMed Pharmaceuticals stocks traded daily (recently around 210290.90909091). InMed Pharmaceuticals's SIR currently stands at 0.11. In other words for every 100,000 InMed Pharmaceuticals stocks traded daily on the market, roughly 110 stocks are currently held short.

However InMed Pharmaceuticals's short interest can also be evaluated against the total number of InMed Pharmaceuticals stocks, or, against the total number of tradable InMed Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InMed Pharmaceuticals's short interest could be expressed as 0% of the outstanding stocks (for every 100,000 InMed Pharmaceuticals stocks in existence, roughly 0 stocks are currently held short) or 0.0008% of the tradable stocks (for every 100,000 tradable InMed Pharmaceuticals stocks, roughly 1 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against InMed Pharmaceuticals.

Find out more about how you can short InMed Pharmaceuticals stock.

InMed Pharmaceuticals stock dividends

We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have InMed Pharmaceuticals stocks ever split?

InMed Pharmaceuticals stocks were split on a 1:33 basis on 6 July 2020. So if you had owned 33 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals stocks – just the quantity. However, indirectly, the new 3200% higher stock price could have impacted the market appetite for InMed Pharmaceuticals stocks which in turn could have impacted InMed Pharmaceuticals's stock price.

InMed Pharmaceuticals stock price volatility

Over the last 12 months, InMed Pharmaceuticals's stocks have ranged in value from as little as $1.76 up to $5.661. A popular way to gauge a stock's volatility is its "beta".

INM.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 1.4116. This would suggest that InMed Pharmaceuticals's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

InMed Pharmaceuticals overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site